Skip to content

A Post-market Observational Study With the easyEndoTM Universal Linear Cutting Stapler in Standard Laparoscopic and Robot-assisted Laparoscopic Roux-en-Y Gastric Bypass (RYGB) Surgery

A Post-market Observational Study With the easyEndoTM Universal Linear Cutting Stapler in Standard Laparoscopic and Robot-assisted Laparoscopic Roux-en-Y Gastric Bypass (RYGB) Surgery

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04543526
Acronym
SIRIUS
Enrollment
0
Registered
2020-09-10
Start date
2021-09-01
Completion date
2024-11-30
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Roux-en-Y Gastric Bypass

Brief summary

The primary purpose of this observational registry is to evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical when used to create anastomoses during standard and robot-assisted laparoscopic Roux-en-Y Gastric Bypass (RYGB) surgery. Stapler performance during surgery as well as post-operative pain and the clinical efficacy of the procedures will be determined as secondary objectives.

Interventions

Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.

Sponsors

Duomed
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient ≥ 18 years of age at study entry. * Patient and investigator signed and dated the informed consent form prior to the index-procedure. * Patient has a BMI ≥ 35 kg/m2 with one or more related co-morbidity. * Patient has a BMI ≥ 40 kg/m2. * Patient is eligible for standard laparoscopic or for robotic-assisted laparoscopic RYGB surgery.

Exclusion criteria

* Patient is unable / unwilling to provide informed consent. * Patient has a history of bariatric surgery. * Patient is unable to comply with the study protocol or proposed follow-up visits. * Patient has a contra-indication for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.

Design outcomes

Primary

MeasureTime frameDescription
Safety - Conversion rate to laparotomyAt index procedure.Number of conversions to laparotomy during the index procedure
Safety - Length of stay at the intensive care unitAt index procedure.Number of days at the intensive care unit after the index procedure.
Safety - Length of stay in the hospital by the modified Post-Anesthesia Discharge Scoring System (PADSS)At index procedure.The Modified PADSS guarantees safe discharge. PADSS is based on the assessment of 6 criteria: vital signs (including blood pressure, pulse, temperature and respiratory rate), ambulation, nausea / vomiting, pain, surgical bleeding and fluid intake / output. Each criterion is given a score from 0 to 2. Patients scoring ≥ 9 are considered fit for discharge, provided that the score for vital signs is not lower than 2 and that none of the other five criteria is 0, even if the total score reaches 9.
Safety - Number of re-interventions and number of participants with (serious) adverse eventsAt index procedure.Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
Safety - Length of stay at the intensive care unit.At discharge, up to 1 week.Number of days at the intensive care unit after the index procedure.

Secondary

MeasureTime frameDescription
Device performance - Technical success of the surgical procedure performed with the deviceAt index procedureNumber of procedures with technical success defined as bariatric surgery as intended, without technical difficulties and without conversion to laparotomy.
Number of participants with a post-operative change of cormorbiditiesFollow-up 3: 12 months after the procedureComorbidities (diabetes mellitus, peripheral arterial disease, coronary arterial disease, sleep disordered breathing, hypertension, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, asthma, congestive heart failure, degenerative joint disease, gastroesophageal reflux, chronic obstructive pulmonary disease, use of immunosuppressants) 12 months after the surgical procedure as compared to the patients' comorbidities at baseline.
Device performance - Scoring of operator satisfactionAt index procedureScoring of: easy of intra-abdominal device positioning, grasping/climbing force, sharpness of the blades, staple-line formation, device stability, device maneuverability, battery power, device consistency and reliability, ergonomic design, hemostasis. Each of the aforementioned items receives a score from 0 to 4, with 0 indicating that the user is very unsatisfied and 4 indicating that the user is very satisfied.
Post-operative pain by means of the Visual Analogue Scale (VAS)At index procedureAssessment of acute post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.
Post-operative food tolerance by means of the food tolerance questionnaireFollow-up 1: 1 month after the procedureFood tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance.
Post-operative change in weightFollow-up 1: 1 month after the procedureWeight loss 1 month after the surgical procedure as compared to the patients' weight at baseline.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026